INOVIO Pharmaceuticals (INO), a biotechnology company, on Wednesday announced positive data from its Phase 1/2 clinical trial of INO-3107, a potential treatment for recurrent respiratory papillomatosis or RRP.
The data, published in Nature Communications, showed that INO-3107 successfully induced new T cell populations that targeted airway and papilloma tissue, leading to a reduction in the need for surgeries.
In the trial, 81 percent of patients experienced a decrease in surgical interventions, with 28 percent of patients requiring no surgeries at all post-treatment.
These results highlight the potential of INO-3107 to provide a significant therapeutic option for RRP patients, who often undergo numerous surgeries due to the recurring growth of papillomas.
Based on these encouraging results, INOVIO plans to submit a biologics license application or BLA for INO-3107 in mid-2025, marking potential progress for the approval of the first DNA medicine for RRP.
The company remains optimistic about INO-3107's ability to transform the treatment paradigm for RRP and reduce the surgical burden for patients.
Currently, INO is trading at $1.94 up by 2.11%.
For comments and feedback: editorial@rttnews.com